市場調查報告書
商品編碼
1154861
全球細胞健康診斷市場規模、份額、行業趨勢分析報告:2022-2028 年各樣本類型、採樣點、測試類型、地區的展望和預測Global Cellular Health Screening Market Size, Share & Industry Trends Analysis Report By Sample Type, By Collection Site, By Test Type, By Regional Outlook and Forecast, 2022 - 2028 |
到 2028 年,全球細胞健康篩查市場規模預計將達到 43 億美元,預測期內復合年增長率為 9.0%。
精準醫學的一個關鍵組成部分是通過細胞健康篩查輕鬆監測和控制治療方案。此外,它越來越多地用於常規體檢,因為它提供有關細胞活動和肌肉質量的信息。
如果您沒有任何症狀,將進行篩查測試以檢查是否存在可能的健康問題或疾病。目標是及早發現、改變生活方式或進行監測,以降低患病的可能性或獲得最佳治療。
COVID-19 影響分析
由於 COVID-19 大流行,提供移動健康篩查產品和服務的公司的收入和基本檢測量有所下降。除了與大流行病相關的政府命令外,運輸限制以及對貨物和原材料進出口的禁令也擾亂了供應鏈。因此,許多公司擴大了他們的產品範圍,將 COVID-19 抗體和分子測試納入其中,以平衡減少的基線測試能力,以應對供應鏈中斷導致的需求減少。我能夠接受。
市場增長因素
世界上老齡化人口的增長
由於衰老和不平衡的生活方式是人體膳食失衡的主要原因,因此細胞健康檢查必不可少。市場上也有補充劑可以提高營養水平。氧化應激、疲勞、壓力以及其他症狀的根本原因是細胞健康狀況不佳。然而,缺乏必需的營養素會逐漸限制細胞的正常活動並導致疾病。 NAD+ 的水平是所有細胞發揮最佳功能所必需的一種□,據說在 40 到 60 歲之間會減少一半。此外,縮短的端粒會導致多種副作用,包括肝病、肺纖維化和骨髓衰竭。
擴大個性化藥物的使用
細胞健康篩查之所以流行,是因為它在個性化醫療中的應用越來越廣泛。國際個性化醫療聯盟 (ICPerMed) 認為,技術創新是推動 PM 以及生物醫學、社會和經濟科學進步的動力。因此,其成功需要對創新和研究進行大量投資。個性化醫療通常由兩部分組成。生物製劑、藥物療法和其他治療干預是第一部分,診斷測試是第二部分。
市場製約因素
細胞篩選試劑盒成本高,缺乏專家
由於便攜式健康檢查套件的成本高昂,大多數人無力使用它們。影響細胞健康篩查生長的另一個方面是樣本脆弱性和試劑盒不穩定性。兩者都會降低程序響應能力和流程效率。它的高維護性使其不適合在所有情況下使用,尤其是在採樣受限的情況下。此外,越來越多的樣品運輸挑戰和不利的退款政策降低了對便攜式健康檢查套件的偏好。
樣本類型展望
按樣本類型,細胞健康篩查市場分為血液、唾液、血清和尿液。 2021 年,尿液樣本部分在細胞健康篩查市場中佔據了很大的收入份額。尿液收集不需要技術人員,而且是非侵入性的,因此對患者友好且速度非常快。此外,研究表明尿液篩查可以準確評估氧化應激。例如,日本研究人員在一篇研究論文中證明,吸煙和氧化應激與尿液中蝶啶化合物的含量有關。因此,體內氧化應激的篩查將會推進,基於尿液樣本的篩查市場有望上升。
採集點前景
細胞健康篩查市場按採集地點細分為家庭、辦公室、醫院和診斷實驗室。 2021 年,家庭部門在細胞健康篩查市場中獲得了可觀的收入份額。這可以通過重要市場中日益增長的健康意識和自我採樣的流行來解釋。自我採樣因其易於使用且不需要專門設備或合格人員而廣受歡迎。由於行動受到限制,COVID-19 大流行還導致了一種普遍的家庭收集趨勢,而且這種趨勢可能會持續下去。
按測試類型劃分的前景
細胞健康篩查市場按檢測類型分為單檢測組和多檢測組。 2021 年,單一檢測試劑盒以最高收入份額主導細胞健康篩查市場。用於單板檢測的產品可為特定類別的疾病提供經濟實惠、準確且快速的篩查。一個簡單的單面板測試使用樣本來檢測可能是疾病前兆的生物標誌物。此類診斷測試可以在企業和個人環境中進行,例如在工作場所或家中。幾分鐘之內,您就會獲得可見且易於理解的定性數據。
氧化應激測試的前景
單試板劃分又分為端粒測試、氧化應激測試、炎症測試、重金屬測試。氧化應激測試將在 2021 年佔據細胞□□健康篩查市場的最大收入份額。這些測試有助於癌症、呼吸系統疾病、糖尿病、心血管疾病和其他疾病。氧化應激是自由基(ROS,活性氧)的產生與體內已有的抗氧化能力 (AC) 之間失衡的結果。當抗氧化力增加時,活性氧的產生受到抑制,反之,當抗氧化力增加時,活性氧的值通常會降低。
區域展望
按地區劃分,分析了北美、歐洲、亞太地區和 LAMEA 的細胞健康篩查市場。 2021 年,北美地區在細胞健康篩查市場的收入份額最大。該地區的主要貢獻者包括健康預期壽命 (HALE)、不斷上升的醫療保健成本以及政府對預防性醫療保健的支持。此外,重要公司的存在、新技術的易於採用、慢性病和傳染病在人口中的流行等都有助於該地區的增長。
細胞健康篩查市場的報導。
報告屬性詳細信息
2021 年市場規模 24 億美元
2028 年市場規模預測 43 億美元
基準年 2021
2018-2020 年
預測期 2022-2028
從 2022 年到 2028 年,收入複合年增長率為 9%。
250頁
表460
報告涵蓋的市場趨勢、盈利預測和預測、細分市場分析、地區/國家細分、公司戰略發展、公司概況
目標細分樣本類型、採樣點、測試類型、地區
美國、加拿大、墨西哥、德國、英國、法國、俄羅斯、西班牙、意大利、中國、日本、印度、韓國、新加坡、澳大利亞、巴西、阿根廷、阿聯酋、沙特阿拉伯、南非、尼日利亞
驅動因素:全球老齡化人口不斷增長
擴大個性化藥物的使用
制約因素:細胞篩選試劑盒成本高,缺乏專業人員
The Global Cellular Health Screening Market size is expected to reach $4.3 billion by 2028, rising at a market growth of 9.0% CAGR during the forecast period.
Cellular health screening is a cutting-edge innovation used to quickly assess cellular health. The screening illustrates how the cells function in relation to the body. The screening aids in determining conditions such as cellular toxicity, fat mass, cellular capabilities, dynamic tissue mass, and extracellular and intracellular liquid levels. The fundamental components of life are cells, which come together to form organs.
Bio-energy is produced by healthy cells, which eventually results in normal health. Since it can accurately assess a person's level of health and provide details about cellular health and performance, cellular health screening has grown in importance in recent years. This screening method helps doctors and other healthcare professionals better understand how cells in the body behave and function.
A key component of precision medicine is the easy monitoring and control of treatment options made possible by cellular health screening. Additionally, it provides information on cellular activity and muscle mass, which has increased its adoption in routine health examinations.
When a person does not exhibit any symptoms of a condition, a screening test is performed to look for probable health issues or diseases. The objective is early identification, lifestyle modifications, or surveillance to lower the likelihood of disease or to identify it soon enough to receive the best possible care.
Covid-19 Impact Analysis
As a consequence of the COVID-19 pandemic, businesses that provide cellular health screening products and services saw a decline in their revenues and base testing volume. Along with the government directives connected to the pandemic, the supply chain was hampered by transportation constraints and prohibitions on the export and import of commodities and raw materials. Consequently, many companies expanded their product offerings to incorporate COVID-19 antibody and molecular testing in response to the fall in demand brought on by the interruption of the supply chain, which could balance the decrease in a base testing capacity.
Market Growth Factors
Rise in the global geriatric population
Cellular health screening is essential because aging and poor lifestyles are the main sources of dietary imbalances in the human body. Commercially available supplements are available to boost nutritional levels. The fundamental cause of oxidative stress, fatigue, stress, as well as other symptoms is a decline in cell health. However, a lack of necessary nutrients will gradually limit cells' ability to operate normally, which will lead to sickness. The levels of NAD+, an enzyme needed by every cell for optimal operation, decrease by half between the ages of 40 and 60. Additionally, a shorter telomere can result in a number of side effects, including liver illness, lung fibrosis, and bone marrow failure.
Expanded Use of Personalized Medicines
The growth of cellular health screening is attributed to its expanding use in personalized medicine. The International Consortium for Personalized Medicine (ICPerMed) considers that technology innovation, along with the advancement of the biomedical, social, and economic sciences, is what propels PM. Therefore, a significant investment in innovation and research is necessary for its successful execution. Personalized medicine generally consists of two components. A biological, medication or any other form of therapeutic intervention is the first, and a diagnostic test is the second.
Market Restraining Factors
High cost of cellular screening kits and lack of specialized workers
The cost of cellular health screening kits can be high, which sustains their usage by the majority beyond a point. Another aspect that has an impact on the growth of Cellular Health Screening is the fragility of samples and the instability of kits. Both of these reduce the responsiveness of the program and the efficiency of the process. Their high maintenance has made them ineligible to be used in every case, especially in cases where the sample collection is limited. Additionally, the rising sample transportation challenges and unfavorable reimbursement policies decline the preference for cellular health screening kits.
Sample Type Outlook
On the basis of sample type, the cellular health screening market is divided into blood, saliva, serum, and urine. The urine sample segment witnessed a significant revenue share in the cellular health screening market in 2021. Since urine collection does not require technical people and is non-invasive, it is patient-friendly and significantly quicker. Additionally, studies have shown that urine screening may accurately assess oxidative stress. For instance, researchers from Japan demonstrated in a study article that smoking and oxidative stress are linked to the level of pteridine compounds in urine. As a result, the market for urine sample type screening is predicted to rise as a result of the growing screening of oxidative stress in the body.
Collection Site Outlook
Based on collection site, the cellular health screening market is segmented into home, office, hospital, and diagnostic labs. The home segment procured a promising revenue share in the cellular health screening market in 2021. This is explained by rising health consciousness and the widespread use of self-sampling in important marketplaces. Self-sampling has become popular because it is simple to use and doesn't call for specialized equipment or qualified personnel. Additionally, the COVID-19 pandemic resulted in a widespread inclination for home collections because of the restrictions on movement, and this inclination will persist for years to come.
Test Type Outlook
Based on test type, the cellular health screening market is categorized into single test panels and multi-test panels. The single test panels dominated the cellular health screening market with the highest revenue share in 2021. Products for single-panel tests offer affordable, precise, and quick screening for a specific, particular class of disease. Simple single panel tests use a sample to detect biomarkers that could be precursors for the disease. Such diagnostic tests are appropriate for both business and personal use, whether conducted in the workplace or at home. Within minutes, tests produce qualitative data that are visible and easy to comprehend.
Oxidative Stress Tests Outlook
The single test panels segment is further divided into telomere tests, oxidative stress tests, inflammation tests, and heavy metals tests. The oxidative stress tests acquired the largest revenue share in the cellular health screening market in 2021. Cancer, respiratory conditions, diabetes, cardiovascular conditions, and other illnesses are helped by these tests. Oxidative stress is a result of an imbalance between the generation of free radicals (ROS, or reactive oxygen species), and the body's already-existing antioxidant capacity (AC). An enhancement in antioxidant capacity frequently results in a decrease in ROS generation, whilst a rise in the AC may result in a drop in ROS values.
Regional Outlook
On the basis of region, the cellular health screening market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North American region recorded the largest revenue share in the cellular health screening market in 2021. Healthy Life Expectancy (HALE), which measures how long people live in good health, rising healthcare costs, and government support for preventative care are some of the major contributing elements in this area. Additionally, the existence of significant important players, the simplicity with which new technologies are adopted, and the prevalence of chronic and infectious diseases among the populace all contribute to regional growth.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Quest Diagnostics Incorporated, OPKO Health, Inc., Laboratory Corporation of America Holdings, Genova Diagnostics, Telomere Diagnostics, Inc., Life Length, S.L., Repeat Diagnostics, Inc., SpectraCell Laboratories, Inc. (Beingmate Group Co. Ltd.), Cell Science Systems Corp. and Segterra, Inc.
Cellular Health Screening Market Report Coverage:
Report Attribute Details
Market size value in 2021 USD 2.4 Billion
Market size forecast in 2028 USD 4.3 Billion
Base Year 2021
Historical period 2018 to 2020
Forecast Period 2022 to 2028
Revenue Growth Rate CAGR of 9% from 2022 to 2028
Number of Pages 250
Tables 460
Report coverage Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling
Segments covered Sample Type, Collection Site, Test Type, Region
Country scope US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Australia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria
Growth Drivers * Rise in the global geriatric population
Expanded Use of Personalized Medicines
Restraints * High cost of cellular screening kits and lack of specialized workers
Market Segments covered in the Report:
By Sample Type
By Collection Site
By Test Type
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures